SS Innovations International, Inc. (NASDAQ: SSII) announced the successful completion of what it said is the world's longest-distance robotic telesurgery, with a robot-assisted cardiac procedure performed across approximately 12,500 miles (20,000 kilometers) of fiber network distance between Guyana and India using the company's SSi Mantra surgical robotic system. The procedure was conducted remotely by CEO and cardiac surgeon Dr. Sudhir Srivastava from Guyana, while the patient-side robotic system operated in India, functioning with network latency of approximately 290-300 milliseconds.
The company said the achievement surpasses its previous telesurgery distance record of approximately 6,250 miles and further demonstrates the capabilities of the SSi Mantra platform in long-distance surgical applications. The milestone coincided with the launch of Guyana's National Robotic Surgery Program and follows regulatory approval for the SSi Mantra in Guyana. SS Innovations noted that 173 telesurgeries have now been performed using the platform globally, including 22 cardiac telesurgeries, which it said makes SSi Mantra the only surgical robotic system currently used for robotic cardiac telesurgery.
This achievement highlights the potential for robotic telesurgery to bridge geographic gaps in healthcare access, particularly for specialized cardiac care. The ability to perform complex procedures over such vast distances could significantly impact patient outcomes in remote or underserved regions, especially in countries like Guyana that are building national robotic surgery programs. The low latency achieved—under 300 milliseconds—is critical for the precision required in cardiac surgery, and SS Innovations' record suggests the technology is maturing for broader clinical adoption.
For the healthcare industry, this milestone underscores the growing viability of telesurgery as a tool for expanding access to expert surgeons without requiring patient travel. It also positions SS Innovations as a key player in the surgical robotics market, which has been dominated by larger competitors. The company's focus on affordability and accessibility could further disrupt traditional models of surgical care delivery.
Investors may see this as a validation of SS Innovations' technology and its potential for global expansion, especially as regulatory approvals expand. The company's track record of 173 telesurgeries, including 22 cardiac procedures, provides real-world evidence of the platform's reliability. However, challenges remain, including the need for robust network infrastructure and regulatory harmonization across countries.
To view the full press release, visit https://ibn.fm/HtXlp.
